Stockscreener 앱 받기
46.78
0.04%
0.02
시간 외 거래:
46.78
전일 마감가:
$46.76
열려 있는:
$46.77
하루 거래량:
4.50M
Relative Volume:
0.91
시가총액:
$3.53B
수익:
-
순이익/손실:
$-275.16M
주가수익비율:
-12.03
EPS:
-3.89
순현금흐름:
$-221.15M
1주 성능:
-0.04%
1개월 성능:
+1.21%
6개월 성능:
+22.14%
1년 성능:
+19.52%
1일 변동 폭
$46.74
$46.80
1주일 범위
$46.71
$46.85
52주 변동 폭
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
명칭
Springworks Therapeutics Inc
전화
203-883-9490
주소
100 WASHINGTON BOULEVARD, STAMFORD, CT
SWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
46.78 | 3.53B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-20 | 개시 | Evercore ISI | Outperform |
| 2024-02-05 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-03-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-04 | 개시 | H.C. Wainwright | Buy |
| 2019-10-08 | 개시 | Cowen | Outperform |
| 2019-10-08 | 개시 | Goldman | Buy |
| 2019-10-08 | 개시 | JP Morgan | Overweight |
| 2019-10-08 | 개시 | Wedbush | Outperform |
모두보기
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
SpringWorks Therapeutics, Inc. Stock Update: Steady Performance Amid Market Trends - Daily Chhattisgarh News
Best Biotech Stocks To Research – June 9th - Defense World
Best Growth Stocks To Follow Now – June 9th - Defense World
Squarepoint Ops LLC Cuts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
88,995 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by RFG Advisory LLC - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Top Growth Stocks To Follow Now – June 4th - Defense World
Best Biotech Stocks Worth Watching – June 4th - Defense World
(SWTX) Proactive Strategies - news.stocktradersdaily.com
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc.SWTX - Business Wire
Nuveen Asset Management LLC Sells 114,138 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - Benzinga
BNP Paribas Financial Markets Acquires Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Promising Growth Stocks To Research – May 28th - Defense World
ProShare Advisors LLC Acquires 5,503 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Merck, SpringWorks receive German antitrust approval for their deal - MLex
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey
BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat
SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com
Growth Stocks To Consider – May 23rd - Defense World
Growth Stocks To ConsiderMay 23rd - MarketBeat
(SWTX) Investment Analysis - news.stocktradersdaily.com
SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World
Rafferty Asset Management LLC Has $4.44 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Velan Capital Investment Management LP Acquires Shares of 185,520 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks’ drug nears EU approval for neurofibromatosis treatment By Investing.com - Investing.com South Africa
SpringWorks Therapeutics (SWTX) Gains EMA Panel Support for Mird - GuruFocus
SpringWorks gets EU endorsement for genetic disorder treatment - Seeking Alpha
SpringWorks’ drug nears EU approval for neurofibromatosis treatment - Investing.com Australia
Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas - marketscreener.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - marketscreener.com
SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN - marketscreener.com
SpringWorks: CHMP Adopts Positive Opinion For Mirdametinib - Nasdaq
Springworks Therapeutics Inc (SWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):